Prevalence and Determinants of the Use of Lipid-Lowering Agents in a Population of Older Hospitalized Patients: the Findings from the REPOSI (REgistro POliterapie Società Italiana di Medicina Interna) Study
Authors:
- On behalf of REPOSI InvestigatorsOIOn behalf of REPOSI Investigators
- Marco BertolottiMBMarco Bertolotti
- Carlotta FranchiCarlotta Franchi
- Marco B. L. RocchiMRMarco B. L. Rocchi
- Alessandro NobiliANAlessandro Nobili
- Lucia CarulliLCLucia Carulli
- 15 March 2017
- journal article
- research article
- Published by Springer Nature in Drugs & Aging
- Vol. 34 (4) , 311-319
Abstract
Older patients are prone to multimorbidity and polypharmacy, with an inherent risk of adverse events and drug interactions. To the best of our knowledge, available information on the appropriateness of lipid-lowering treatment is extremely limited.Keywords
This publication has 49 references indexed in Scilit:
- Risk for cardiovascular events in an Italian population of patients with type 2 diabetesNutrition, Metabolism and Cardiovascular Diseases, 2011
- Need for Redesigning Pharmacologic Research in Older Individuals. A Position Statement of the Geriatric Working Group of the Agenzia Italiana del Farmaco (AIFA)The Journals of Gerontology, Series A: Biological Sciences and Medical Sciences, 2010
- Safety and Efficacy of Ezetimibe Added to Atorvastatin Versus Up Titration of Atorvastatin to 40 mg in Patients ≥65 Years of Age (from the ZETia in the ELDerly [ZETELD] Study)The American Journal of Cardiology, 2010
- Statin therapy in the elderly: A reviewArchives of Gerontology and Geriatrics, 2010
- The challenge of safer prescribingBMJ, 2008
- Age‐related changes in bile acid synthesis and hepatic nuclear receptor expressionEuropean Journal of Clinical Investigation, 2007
- Overcoming ???Ageism??? Bias in the Treatment of HypercholesterolaemiaDrug Safety, 2006
- Cumulative Illness Rating Scale was a reliable and valid index in a family practice contextJournal of Clinical Epidemiology, 2005
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Lipids and risk of coronary heart disease The Framingham StudyAnnals of Epidemiology, 1992